Skip to main content

Table 2 Baseline patient demographic details in Study 1222.27

From: Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

 

Total (n = 198)

Age, mean (SD), years

45.0 (11.8)

Male, n (%)

86 (43.4)

Asthma diagnosis, mean (SD), years

20.4 (13.2)

Body mass index, mean (SD), kg/m2

27.9 (5.3)

Smoking status, n (%)

 

     Current smoker

1 (0.5)

     Ex-smoker

51 (25.8)

     Never smoker

146 (73.7)

Smoking history, mean (SD), pack-yearsa

5.4 (2.7)

Pre-bronchodilator FEV1, mean (SD), L

2.37 (0.63)

Post-bronchodilator FEV1, mean (SD), L

2.92 (0.79)

Change in FEV1 from pre-bronchodilator (SD), L

0.55 (0.30)

Post-bronchodilator FEV1:FVC ratio, mean (SD), %

71.9 (8.8)

  1. aBased on n = 52 (i.e. only current and ex-smokers were included in this analysis)
  2. SD: standard deviation; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity